|
|
|
| Adverse events following immunization of measles,mumps and rubella,ormeasles and rubella combined attenuated live vaccine among8-month-old children in Jiaxing |
| DU Zhequn, HU Jie, SHEN Guochu, XU Rongquan
|
| Jiaxing Center for Disease Control and Prevention, Jiaxing, Zhejiang 314050, China |
|
|
|
|
Abstract Objective To analyze the surveillance of adverse event following immunization (AEFI) among 8-month-old children in Jiaxing who received measles, mumps and rubella combined attenuated live vaccine (MMR) or measles and rubella combined attenuated live vaccine (MR) , so as to provide support for the adjustment of vaccine immunization strategy.Methods The AEFI information of MR (December 1, 2016 to April 30, 2018) and MMR (December 1, 2018 to April 30, 2020) was collected through National AEFI Monitoring Information Management System to compare the incidence, clinical features, occurred time of AEFI as well as combined vaccination.Results Totally 94 287 doses of MR and 79 994 doses of MMR were administered, 145 and 156 cases of AEFI were reported, and the incidence rate was 15.38/10 000 after MR vaccination, which was lower than 19.50/10 000 after MMR vaccination (P<0.05). Most reported AEFI were abnormal reactions, with 93 cases (11.63/10 000) after MR vaccination and 101 cases (10.71/10 000) after MMR vaccination, among which 72 cases (7.64/10 000) and 76 cases (9.50/10 000) respectively had allergic rash. The AEFI cases mainly occurred less than one day after vaccination, with 113 cases (77.93%) after MR vaccination and 125 cases (80.13%) after MMR vaccination. Most cases of AEFI were vaccinated with Japanese encephalitis attenuated live vaccine (JEV), with 103 cases (71.03%) after MR vaccination and 102 cases (65.38%) after MMR vaccination.Conclusions The MMR is safety for 8-month-old children in Jiaxing. Most AEFI cases had abnormal reactions, occur within one day after vaccination, and are vaccinated with JEV.
|
|
Received: 28 June 2020
Revised: 17 August 2020
Published: 09 November 2020
|
|
|
|
|
|
[1] 岑祚洁,韦娜,蒙婞婞,等.广西南宁市江南区2008—2017年麻疹、流行性腮腺炎和风疹的流行趋势及特征[J].广西医科大学学报,2018,35(6):877-880.
[2] 何寒青,张兵,严睿,等.不同免疫程序接种2剂麻疹-流行性腮腺炎-风疹联合减毒活疫苗的卫生经济学评价[J].中华流行病学杂志,2016,37(8):1121-1126.
[3] 王晶晶,周杰,汤喜红,等.2017—2018年上海市金山区疑似预防接种异常反应监测分析[J].公共卫生与预防医学,2019,30(4):99-102.
[4] 王三凤,杨凯朝,史鲁斌,等.河南省2016—2018年含麻疹和风疹成分联合疫苗疑似预防接种异常反应监测[J].中国疫苗和免疫,2020,26(3):329-331,335.
[5] 中国政府网.关于印发《全国疑似预防接种异常反应监测方案》的通知[EB/OL].(2010-06-14)[2020-08-17].http://www.nhc.gov.cn/jkj/s3581/201402/5dd5633d93174a7c8e93d8af7579a613.shtml?from=timeline.
[6] 许涤沙,李克莉,武文娣,等.中国2016 年疑似预防接种异常反应监测数据分析[J].中国疫苗和免疫,2018,24(3):299-309.
[7] 陈玉娟,龚琼宇,李琼芬,等.云南省2011—2015年含麻疹成分疫苗疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2018,24(1):69-72.
[8] 彭时辉,文海蓉,许波,等.江西省南昌市2012—2015年麻疹风疹联合减毒活疫苗疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2016,22(6):679-683.
[9] 卞春峰. 2008—2018年南通市通州区平潮镇疑似预防接种异常反应监测结果[J].职业与健康,2019,35(21):2931-2935.
[10] 高波,孙灵英,袁月荣,等.浙江省宁波市江东区2010—2015年疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2017,23(3):322-326.
[11] 赵杨升,孙青,王琳琳,等.我国联合疫苗产业发展现状、问题及对策[J].中国医药工业杂志,2018,49(9):1306-1312.
[12] 蒋薇薇,崔光辉,李岩岩,等.蜀山区儿童疑似预防接种异常反应监测分析[J].预防医学,2018,30(8):789-793.
[13] 段良松,李成华,黄凯,等.2011—2018年郴州市A群脑膜炎球菌多糖疫苗疑似预防接种异常反应监测结果[J].预防医学,2020,32(4):402-404.
[14] 朱红飞.儿童预防接种不良反应发生因素及护理研究[J].实用临床护理学电子杂志,2019,4(14):1,7.
[15] 俞柳燕,陈深侠,凌罗亚,等. 8月龄儿童接种麻疹-腮腺炎-风疹三联疫苗免疫效果及接种安全性观察[J].中国预防医学杂志,2008,9(3):206-207.
[16] HE H Q,CHEN E F,CHEN H P,et a1.Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in children[J].Vaccine,2014,32(31):4001-4005.
[17] 黄蓉,肖雷,王凤双,等.2015—2017年北京市顺义区疑似预防接种异常反应监测数据分析[J].首都公共卫生,2019,3(3):158-161.
[18] 陈阿群,陈成连,叶秀华,等.江门市2012—2018年疑似预防接种异常反应监测数据分析[J].实用预防医学,2020,27(5):558-561.
[19] 陈碧玉,曾雪霞,陈少明,等.免疫策略调整前后海南省脊髓灰质炎疫苗疑似预防接种异常反应监测[J].中国疫苗和免疫, 2019,25(4):444-448.
[20] 许玉祥,许二萍,李倩,等.国产乙脑灭活疫苗安全性主动监测结果分析[J].浙江预防医学,2016,28(6):600-603. |
|
|
|
